Document 0701
 DOCN  M9440701
 TI    Correlations between the in vitro and in vivo activity of anti-HIV
       agents: implications for future drug development.
 DT    9404
 AU    Yarchoan R; Broder S; Medicine Branch, National Cancer Institute, NIH,
       Bethesda, MD; 20892.
 SO    J Enzym Inhib. 1992;6(1):99-111. Unique Identifier : AIDSLINE
       MED/94132926
 AB    Some 10 years after the first recognition of acquired immunodeficiency
       syndrome (AIDS) as a new syndrome, we have identified a number of
       molecular targets to interrupt the replicative cycle of human
       immunodeficiency virus (HIV), the causative agent. A number of
       dideoxynucleosides have been identified as having anti-HIV activity in
       vitro, and several of these have been found to have clinical activity in
       patients. In contrast, while a number of agents have been found to block
       viral binding to the target cell in vitro, these agents have generally
       not shown clear-cut evidence of clinical activity. Agents which act at a
       variety of steps in the HIV replicative cycle are now under development,
       and it is likely that we will have an increased armamentarium to fight
       this disease in the near future.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Antiviral
       Agents/*PHARMACOLOGY/*THERAPEUTIC USE  Drug Therapy, Combination  Human
       HIV/*DRUG EFFECTS/GROWTH & DEVELOPMENT  HIV Protease
       Inhibitors/PHARMACOLOGY  Reverse Transcriptase/ANTAGONISTS & INHIB
       Virus Replication/DRUG EFFECTS  JOURNAL ARTICLE  REVIEW  REVIEW,
       ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).